{"id":"https://openalex.org/W7214948253","doi":"https://doi.org/10.3389/fimmu.2026.1908442","title":"Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)","display_name":"Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)","publication_year":2026,"publication_date":"2026-09-30","ids":{"openalex":"https://openalex.org/W7214948253","doi":"https://doi.org/10.3389/fimmu.2026.1908442","pmid":"https://pubmed.ncbi.nlm.nih.gov/42877103","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13662084"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.1908442","doi":"https://doi.org/10.3389/fimmu.2026.1908442","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1908442","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1908442/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1908442/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5136769415","display_name":"Rachael McClenahan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799409606","display_name":"Reading Hospital","ror":"https://ror.org/04kk13p96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799409606"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachael McLenahan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5136044173","display_name":"Laith Alamlih","orcid":"https://orcid.org/0000-0003-1356-0835","observed_orcids":["https://orcid.org/0000-0003-1356-0835"]},"institutions":[{"id":"https://openalex.org/I21215505","display_name":"Al-Quds University","ror":"https://ror.org/04hym7e04","country_code":"PS","type":"education","lineage":["https://openalex.org/I21215505"]}],"countries":["PS"],"is_corresponding":false,"raw_author_name":"Laith Al-Amlih","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1356-0835","affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.73135817,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1908442","last_page":"1908442"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.906000018119812},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-inhibitors","display_name":"tumor necrosis factor inhibitors","score":0.9610000252723694},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.6890000104904175},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9380000233650208},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.6899999976158142},{"id":"https://openalex.org/keywords/heart-failure-hospitalization","display_name":"heart failure hospitalization","score":0.972000002861023},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":1.0},{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":0.8820000290870667},{"id":"https://openalex.org/keywords/baricitinib","display_name":"baricitinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/upadacitinib","display_name":"upadacitinib","score":1.0},{"id":"https://openalex.org/keywords/target-trial-emulation","display_name":"target trial emulation","score":0.6430000066757202},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.6129999756813049},{"id":"https://openalex.org/keywords/e-values","display_name":"E-value","score":0.46700000762939453},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.5450000166893005},{"id":"https://openalex.org/keywords/biologic-therapy-comparison","display_name":"biologic therapy comparison","score":0.5709999799728394},{"id":"https://openalex.org/keywords/cataract","display_name":"cataract","score":0.5600000023841858}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9509999752044678},{"id":"https://openalex.org/C2780739214","wikidata":"https://www.wikidata.org/wiki/Q6723023","display_name":"Mace","level":4,"score":0.7752000093460083},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7142999768257141},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7009999752044678},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6022999882698059},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.5983999967575073},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5443999767303467},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.5047000050544739},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.48590001463890076},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.414000004529953},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.3869999945163727},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.3736000061035156},{"id":"https://openalex.org/C50440223","wikidata":"https://www.wikidata.org/wiki/Q1475848","display_name":"Risk factor","level":2,"score":0.351500004529953},{"id":"https://openalex.org/C120195587","wikidata":"https://www.wikidata.org/wiki/Q2138790","display_name":"Absolute risk reduction","level":3,"score":0.3328000009059906},{"id":"https://openalex.org/C2779668873","wikidata":"https://www.wikidata.org/wiki/Q6693756","display_name":"Lower risk","level":3,"score":0.3163999915122986},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.2906000018119812},{"id":"https://openalex.org/C11783203","wikidata":"https://www.wikidata.org/wiki/Q5478027","display_name":"Framingham Risk Score","level":3,"score":0.28619998693466187},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.2800999879837036},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.2727000117301941},{"id":"https://openalex.org/C78085059","wikidata":"https://www.wikidata.org/wiki/Q641303","display_name":"Ejection fraction","level":3,"score":0.27140000462532043},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2712000012397766},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.27000001072883606},{"id":"https://openalex.org/C112392421","wikidata":"https://www.wikidata.org/wiki/Q903451","display_name":"Janus kinase","level":3,"score":0.26739999651908875},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.26260000467300415},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26179999113082886},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.25}],"mesh":[{"descriptor_ui":"D000075242","descriptor_name":"Janus Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000075242","descriptor_name":"Janus Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000079424","descriptor_name":"Tumor Necrosis Factor Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000079424","descriptor_name":"Tumor Necrosis Factor Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.3389/fimmu.2026.1908442","doi":"https://doi.org/10.3389/fimmu.2026.1908442","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1908442","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1908442/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"doi:10.2139/ssrn.6687613","doi":"https://doi.org/10.2139/ssrn.6687613","is_oa":true,"landing_page_url":"https://doi.org/10.2139/ssrn.6687613","pdf_url":null,"source":{"id":"https://openalex.org/S4210172589","display_name":"SSRN Electronic Journal","issn_l":"1556-5068","issn":["1556-5068"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1318003438","host_organization_name":"RELX Group (Netherlands)","host_organization_lineage":["https://openalex.org/I1318003438"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:13662084","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13662084/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13662084/pdf/fimmu-17-1908442.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:42877103","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42877103","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:a0788f18a9a14f8c92317db4472399bf","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/a0788f18a9a14f8c92317db4472399bf","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.1908442","doi":"https://doi.org/10.3389/fimmu.2026.1908442","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1908442","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1908442/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214948253.pdf","grobid_xml":"https://content.openalex.org/works/W7214948253.grobid-xml"},"referenced_works_count":27,"referenced_works":["https://openalex.org/W1976068756","https://openalex.org/W2015410646","https://openalex.org/W2036193982","https://openalex.org/W2053237747","https://openalex.org/W2065268028","https://openalex.org/W2075619622","https://openalex.org/W2164858045","https://openalex.org/W2169773326","https://openalex.org/W2298338128","https://openalex.org/W2321946146","https://openalex.org/W2530335997","https://openalex.org/W2767394258","https://openalex.org/W3126579487","https://openalex.org/W4205998736","https://openalex.org/W4210529991","https://openalex.org/W4232642069","https://openalex.org/W4296696831","https://openalex.org/W4388947809","https://openalex.org/W4388968836","https://openalex.org/W4406943993","https://openalex.org/W4407388966","https://openalex.org/W4409441549","https://openalex.org/W4409825644","https://openalex.org/W4410268088","https://openalex.org/W4415356337","https://openalex.org/W4415660346","https://openalex.org/W7138837279"],"related_works":["https://openalex.org/W7160321389","https://openalex.org/W4409291197","https://openalex.org/W4366290662","https://openalex.org/W7222719591","https://openalex.org/W4388947809","https://openalex.org/W4396826807","https://openalex.org/W4403014796","https://openalex.org/W4409825644","https://openalex.org/W4399746293","https://openalex.org/W2945228415"],"abstract_inverted_index":{"Objectives:":[0],"This":[1,280],"study":[2],"aims":[3],"to":[4,152],"compare":[5],"cardiovascular":[6,27,44,65,239,313],"and":[7,42,79,104,131,146,170,203,288],"mortality":[8,196,266,318],"outcomes":[9,97],"of":[10,283],"Janus":[11],"kinase":[12],"inhibitors":[13,19],"(JAKi)":[14],"versus":[15],"tumor":[16],"necrosis":[17],"factor":[18,46],"(TNFi)":[20],"in":[21,53,193,264,292],"rheumatoid":[22],"arthritis":[23],"(RA)":[24],"at":[25],"elevated":[26],"risk":[28,45,66,133,240],"using":[29],"target":[30],"trial":[31],"emulation.":[32],"Methods:":[33],"Within":[34],"TriNetX,":[35],"adults":[36],"with":[37,108,126,214,251,273],"RA":[38],"aged":[39],"\u226550":[40],"years":[41],"\u22651":[43],"initiating":[47],"JAKi":[48,246],"or":[49,91,195,242,259],"TNFi":[50],"were":[51,98,138],"compared":[52],"a":[54,111,190,270],"new-user,":[55],"active-comparator":[56],"design.":[57],"Improved":[58],"1:1":[59],"propensity":[60],"score":[61],"matching":[62],"incorporated":[63],"demographics,":[64],"factors,":[67],"comorbidities,":[68],"individual":[69,278],"conventional":[70],"synthetic":[71],"DMARDs,":[72],"oral":[73],"corticosteroids,":[74],"prior":[75],"non-TNF":[76],"biologic":[77],"exposure,":[78],"baseline":[80],"inflammatory":[81],"markers.":[82],"The":[83,303],"primary":[84],"outcome":[85],"was":[86,212,226,235,248,267,282,289],"MACE":[87,194,253,305],"(nonfatal":[88],"myocardial":[89],"infarction":[90],"nonfatal":[92],"ischemic":[93],"stroke);":[94],"the":[95,178,206,317],"secondary":[96,271],"all-cause":[99,265],"mortality,":[100],"heart":[101,164,256],"failure":[102,165,257],"hospitalization,":[103,258],"venous":[105],"thromboembolism":[106],"(VTE),":[107],"cataract":[109],"as":[110,269,311,320],"prespecified":[112],"negative":[113,179],"control.":[114],"Follow-up":[115],"began":[116],"90":[117],"days":[118],"after":[119],"initiation.":[120],"Cox":[121],"models":[122],"estimated":[123],"hazard":[124],"ratios,":[125],"5-year":[127],"Kaplan-Meier":[128],"cumulative":[129],"incidences":[130],"absolute":[132],"differences":[134],"per":[135,159],"1,000.":[136],"Cohorts":[137],"separately":[139],"matched":[140],"by":[141,237],"agent,":[142],"sex,":[143,238],"cardiovascular-risk":[144],"stratum,":[145],"index":[147,243],"era;":[148],"E-values":[149],"quantified":[150],"sensitivity":[151],"unmeasured":[153],"confounding.":[154],"Results:":[155],"=":[156],"0.0014;":[157],"+10.4":[158],"1,000;":[160],"E-value":[161],"1.586),":[162],"whereas":[163],"hospitalization":[166],"(HR":[167,172,184,216,228],"1.019,":[168],"0.955-1.088)":[169],"VTE":[171,213],"1.054,":[173],"0.961-1.156)":[174],"did":[175],"not":[176,249,290,308],"differ;":[177],"control":[180],"showed":[181,189],"no":[182,274],"excess":[183,192,252,263],"0.934,":[185],"0.867-1.007).":[186],"No":[187,231],"agent":[188],"significant":[191,209],"(mortality":[197],"HR":[198],"1.052":[199],"tofacitinib,":[200],"1.213":[201],"baricitinib,":[202],"1.090":[204],"upadacitinib);":[205],"only":[207],"nominally":[208],"agent-level":[210],"finding":[211],"baricitinib":[215],"1.364,":[217],"1.028-1.809;":[218],"198":[219],"events).":[220],"A":[221,261],"three-component":[222],"composite":[223],"including":[224],"death":[225],"non-significant":[227],"1.058,":[229],"0.992-1.127).":[230],"consistent":[232],"effect":[233],"modification":[234],"seen":[236],"burden,":[241],"year.":[244],"Conclusion:":[245],"initiation":[247],"associated":[250],"(primary":[254],"outcome),":[255],"VTE.":[260],"modest":[262,284],"observed":[268],"outcome,":[272],"signal":[275,319],"for":[276],"any":[277,293],"agent.":[279],"association":[281],"robustness":[285],"(E-value":[286],"1.586)":[287],"reproduced":[291],"agent-specific":[294],"cohort,":[295],"so":[296],"residual":[297],"channeling":[298],"bias":[299],"cannot":[300],"be":[301,309],"excluded.":[302],"null":[304],"result":[306],"should":[307],"read":[310],"class-wide":[312],"safety":[314],"reassurance":[315],"nor":[316],"an":[321],"established":[322],"causal":[323],"effect.":[324]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-10-01T00:00:00"}